Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADAM metallopeptidase with thrombospondin type 1 motif 6 (ADAMTS6) is a secreted, catalytically active metalloproteinase of the ADAMTS family, characterized by a metalloprotease domain, disintegrin-like domain, and multiple thrombospondin type 1 repeats. ADAMTS6 modulates the extracellular matrix by cleaving specific proteins, especially impacting microfibril assembly and cell-cell junction integrity. Increased ADAMTS6 activity disrupts epithelial cell-cell junctions (tight and adherens junctions), reduces deposition of microfibrils (such as fibrillin-1 and fibronectin), and depletes cell surface heparan sulfate by proteolytic cleavage, including of syndecan-4. These actions influence tissue architecture and homeostasis, and aberrant expression or activity is associated with connective tissue abnormalities, including predisposition to hernias and possible roles in other connective tissue diseases[1][2][3][6].
Proteolytic cleavage of extracellular matrix components. Disruption of cell surface heparan sulfate and associated proteoglycans (such as syndecan-4).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ADAM metallopeptidase with thrombospondin type 1 motif 6 (ADAMTS6).